Skip to main content
SteadySharesSteadySharesSteadyStShares
The market
MarketsDiscover
Follow the money
Super InvestorsPolitician TradesCrypto Desk
Yours
My WealthNews
Settings Sign in to save your work
Pre-market
SteadySharesMarketsDiscoverSuper InvestorsMy WealthPoliticiansCryptoNews
DiscoverQIA.DE
HealthcareGEREUR

Qiagen N.V.

€0012345678900123456789.0012345678900123456789+0.8%
52w low (est.) €29.58€45.85 52w high (est.)
Market data · updated 7m ago
Peers
Market data
Market cap
EUR8.49B
52w range
EUR27.56 - EUR47.60
Beta
0.64
Sector
Healthcare
Data quality
100/100
Valuation
P/E ratio
20.9x
DCF fair value
EUR14.62
Margin of safety
-60.1%
Forward P/E
16.0x
PEG ratio
1.03
Dividend yield
0.85%
Quality & efficiency
Moat score
63/100
Return on equity
11.9%
Profit margin
19.2%
Debt / equity
0.50
Growth & analysts
Revenue growth
+1.8%
Analyst target
EUR38.44
Target upside
+5.0%
Analysts
7
Run the 10-point checklist before you buy How these numbers are made

About Qiagen N.V.

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

Valuation

ValueGrowthProfitHealthIncome34QUALITY
Overall Rating
38
Reduce
Reduce

Derived from filed metrics · High confidence (100% of the inputs available)

Moat Score63
DCF Intrinsic Value
EUR14.62-60.1% downside

Moat, DCF and rating computed by our valuation engine (ported from the original Python model).

Fundamentals

Market Cap
EUR8.49B
P/E Ratio
20.9
Dividend Yield
0.85%
Revenue Growth
+1.8%
Profit Margin
19.2%
ROE
11.9%
Debt / Equity
0.50
Beta
0.64
vs Healthcare sector:P/E 21 vs 28 · cheaperMoat 63 vs 7Yield 0.85% vs 0.3%

Statistics

Similar Stocks · Healthcare

LLY73
$920.00+0.7%
AZN.L72
£105.20+0.6%
UNH71
$492.10+1.6%
JNJ70
$146.20-0.2%

Latest News · QIA.DE